Natalizumab use in pediatric patients with relapsing-remitting multiple sclerosis

European Journal of Paediatric Neurology

Volumn 17, Issue 1, 2013, Pages 50-54

  Arnal Garcia, Carmen ^a   García Montero, Ma Rosa ^b   Málaga, Ignacio ^c   Millán Pascual, Jorge ^d   Oliva Nacarino, Pedro ^c   Ramió Torrentà, Lluís ^e   Oreja Guevara, Celia ^f  

^a HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

^b HOSPITAL VIRGEN DE LA SALUD   (Spain)

^c HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^d La Mancha Centro General Hospital   (Spain)

^e HOSPITAL JOSEP TRUETA   (Spain)

^f HOSPITAL CLÍNICO SAN CARLOS   (Spain)

Author keywords

Childhood; Children; Multiple sclerosis; Natalizumab; Pediatric; Treatment

Indexed keywords

AZATHIOPRINE; BETA1A INTERFERON; GADOLINIUM; GLATIRAMER; INTERFERON BETA SERINE; NATALIZUMAB;

ACUTE GASTROENTERITIS; ADOLESCENT; ALLERGIC REACTION; ARTICLE; CHILD; CLINICAL ARTICLE; DEMOGRAPHY; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EXPANDED DISABILITY STATUS SCALE; FEMALE; HUMAN; MALE; MULTIPLE SCLEROSIS; PHARYNGITIS; PRESCHOOL CHILD; PRIORITY JOURNAL; RELAPSE; RETROSPECTIVE STUDY; SCHOOL CHILD;

ADOLESCENT; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTICONVULSANTS; CHILD; COMPASSIONATE USE TRIALS; FEMALE; HUMANS; MALE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; RETROSPECTIVE STUDIES;

EID: 84872120847     PISSN: 10903798     EISSN: 15322130     Source Type: Journal    
DOI: 10.1016/j.ejpn.2012.09.004     Document Type: Article

References (26)

1. A. Ghezzi, V. Deplano, and J. Faroni Multiple sclerosis in childhood: clinical features of 149 cases Mult Scler 3 1997 43 46
2. I.L. Simone, D. Carrara, and C. Tortorella Course and prognosis in early-onset MS: comparison with adult-onset forms Neurology 59 2002 1922 1928
3. C. Renoux, S. Vukusic, and Y. Mikaeloff Natural history of multiple sclerosis with childhood onset N Engl J Med 356 2007 2603 2613
4. L. Kappos, C.H. Polman, and M.S. Freedman Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes Neurology 67 2006 1242 1249
5. B. Kornek, G. Bernert, C. Balassy, J. Geldner, D. Prayer, and M. Feucht Glatiramer acetate treatment in patients with childhood and juvenile onset multiple sclerosis Neuropediatrics 34 2003 120 126
6. E. Waubant, J. Hietpas, and T. Stewart Interferon beta-1a in children with multiple sclerosis is well tolerated Neuropediatrics 32 2001 211 213
7. B. Banwell, A.T. Reder, and L. Krupp Safety and tolerability of interferon beta-1b in pediatric multiple sclerosis Neurology 66 2006 472 476
8. R.E. Appleton, and M. Boggild Natalizumab in paediatric multiple sclerosis and service implication Dev Med Child Neurol 51 2009 758 759
9. C.H. Polman, P.W. O'Connor, and E. Havrdova A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis N Engl J Med 354 2006 899 910
10. G. Borriello, L. Prosperini, A. Luchetti, and C. Pozzilli Natalizumab treatment in pediatric multiple sclerosis: a case report Eur J Paediatr Neurol 13 2009 67 71
11. P. Huppke, W. Stark, C. Zürcher, B. Huppke, W. Brück, and J. Gärtner Natalizumab use in pediatric multiple sclerosis Arch Neurol 65 2008 1655 1658
12. A. Ghezzi, V. Brescia-Morra, and F. Bortolon Safety and effectiveness of natalizumab in paediatric multiple sclerosis: results of 17 patients Mult Scler 15 Suppl. 2 2009 774
13. E. Yeh, L. Krupp, N. Kuntz, and J. Ness Use of natalizumab in pediatric MS patients: a pediatric network experience Neurology 74 9 Suppl. 2 2010 A100
14. C. Pandolfini, and M. Bonati A literature review on off-label drug use in children Eur J Pediatr 164 9 2005 552 558
15. R.A. Rudick, and C.H. Polman Current approaches to the identification and management of breakthrough disease in patients with multiple sclerosis Lancet Neurol 8 2009 545 559 19446274
16. E.A. Yeh, E. Waubant, and L.B. Krupp Multiple sclerosis therapies in pediatric patients with refractory multiple sclerosis Arch Neurol 68 2011 437 444
17. N. Putzki, O. Yaldizli, R. Bühler, G. Schwegler, D. Curtius, and B. Tettenborn Natalizumab reduces clinical and MRI activity in multiple sclerosis patients with high disease activity: results from a multicenter study in Switzerland Eur Neurol 63 2010 101 106
18. N. Putzki, K. Kollia, S. Woods, E. Igwe, H.C. Diener, and V. Limmroth Natalizumab is effective as second line therapy in the treatment of relapsing remitting multiple sclerosis Eur J Neurol 16 2009 424 426
19. L. Kappos, D. Bates, and H. Hartung Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring Lancet Neurol 6 2007 431 441
20. A. Ghezzi Therapeutic strategies in childhood multiple sclerosis Ther Adv Neurol Disord 3 2010 217 228
21. O. Stüve, C.M. Marra, and K.R. Jerome Immune surveillance in multiple sclerosis patients treated with natalizumab Ann Neurol 59 2006 743 747
22. Sandrock A, Hotermans C, Richman S, et al. Risk stratification for progressive multifocal leukoencephalopathy (PML) in MS patients: role of prior immunosuppressant use, natalizumab-treatment duration, and anti-JCV antibody status. In: 63rd Annual meeting of the American Academy of Neurology, April 9-16, 2011. Honolulu, Hawaii, USA.
23. E.A. Yeh, and B. Weinstock-Guttman Natalizumab in pediatric multiple sclerosis patients Ther Adv Neurol Disord 3 2010 293 299
24. J.S. Hyams, D.C. Wilson, and A. Thomas Natalizumab therapy for moderate to severe Crohn disease in adolescents J Pediatr Gastroenterol Nutr 44 2007 185 191
25. ®))-2011 Neurologia 27 7 2012 432 441
26. M.D. Kaufman, R. Lee, and H.J. Norton Course of relapsing-remitting multiple sclerosis before, during and after natalizumab Mult Scler 17 2011 490 494